Amit Mitra
Affiliations: | Drug Discovery and Development | Auburn University, Auburn, AL, United States |
Google:
"Amit Mitra"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mitra Ghosh T, Mazumder S, Davis J, et al. (2023) Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Research Communications. 3: 1286-1311 |
| Davis JT, Ghosh TM, Mazumder S, et al. (2023) Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences. 24 |
| Mazumder S, Mitra Ghosh T, Mukherjee UK, et al. (2022) Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer. Cancers. 14 |
| Kumar H, Mazumder S, Sharma N, et al. (2022) Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Frontiers in Oncology. 12: 842200 |
| Kumar H, Mazumder S, Chakravarti S, et al. (2022) secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer Journal. 12: 39 |
| Mitra Ghosh T, Kansom T, Mazumder S, et al. (2021) . The Journal of Pharmacology and Experimental Therapeutics |
| Mitra Ghosh T, White J, Davis J, et al. (2021) Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Frontiers in Pharmacology. 12: 736951 |
| Kumar H, Mukherjee UK, Chen L, et al. (2019) In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma Blood. 134: 5543-5543 |
| Kumar H, Mukherjee UK, Mazumder S, et al. (2019) Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma Blood. 134: 4418-4418 |
| Ghosh TM, Mitra AK, Davis J, et al. (2019) Abstract LB-267: Transcriptomic and epigenomic analysis of metastatic castration-resistant prostate cancer and a pan-cancer analysis of its genetic signatures Cancer Research |